Some of the synthesized analogs showed considerable antiproliferation properties (MTT assay) against MCF7, ZR-75-1 (wild-type p53), and BT-474 (mutated-type p53) breast cancer cell lines (Supplementary Figure S22). This evidence concerns the gene TP53 and breast carcinoma.